Y Intercept Hong Kong Ltd Purchases 1,143 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Y Intercept Hong Kong Ltd increased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 14.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,090 shares of the biotechnology company’s stock after buying an additional 1,143 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Sarepta Therapeutics were worth $1,105,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its position in shares of Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares during the period. Wellington Management Group LLP grew its stake in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Sarepta Therapeutics by 9.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock valued at $94,148,000 after purchasing an additional 63,437 shares during the period. Finally, Erste Asset Management GmbH bought a new position in Sarepta Therapeutics during the 3rd quarter valued at approximately $79,425,000. 86.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on SRPT shares. Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a research note on Tuesday, February 11th. They set a “hold” rating and a $136.00 target price on the stock. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. HC Wainwright reaffirmed a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 13th. Finally, Robert W. Baird decreased their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Trading Down 0.1 %

NASDAQ:SRPT opened at $106.86 on Thursday. The stock has a market cap of $10.21 billion, a price-to-earnings ratio of 85.49 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company’s 50 day moving average price is $116.47 and its 200-day moving average price is $122.90. Sarepta Therapeutics, Inc. has a 52 week low of $101.15 and a 52 week high of $173.25.

Insider Activity at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.